On this episode of INsights & OUTcomes, we sit down with Mark Larkin, real-world evidence expert at Vitaccess, to explore why the "gold standard" of clinical trials often falls short the moment a treatment hits the real world.
We dive deep into the shift toward patient-centered science, discussing the critical difference between a study that is truly patient-centric versus one that is merely "patient-advised." Mark explains how longitudinal data is filling the gaps left by RCTs, from capturing the granular daily impacts of rare diseases to understanding the ripple effect of treatments on caregivers.
Watch the full conversation here: https://youtu.be/ApKzubFy4Ao
Podden och tillhörande omslagsbild på den här sidan tillhör
HealthEconomics.com. Innehållet i podden är skapat av HealthEconomics.com och inte av,
eller tillsammans med, Poddtoppen.
